El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Español (Latinoamérica)
Vertex Pharmaceuticals Inc
Cerrado
SectorSalud
451.57 -2.29
Resumen
Variación precio
24h
Mínimo
450.84
Máximo
462.27
Ingresos | 108M 1.2B |
|---|---|
Ventas | 151M 3.2B |
P/B Media del Sector | 30.404 57.833 |
BPA | 5.03 |
Margen de beneficio | 36.909 |
Empleados | 6,400 |
EBITDA | -2.6M 1.4B |
Recomendaciones | Compra Fuerte |
|---|---|
Estimación a 12 meses | +20.19% upside |
Próximas Ganancias | 4 may 2026 |
|---|
Capitalización de Mercado | -2.3B 118B |
|---|---|
Apertura anterior | 453.86 |
Cierre anterior | 451.57 |
Noticias sobre sentimiento de mercado
By Acuity
34%
66%
97 / 351 Clasificación en Healthcare
Puntuación técnica
By Trading Central
Confianza
Very Strong Bearish Evidence
Vertex Pharmaceuticals Inc Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Vertex Pharmaceuticals Inc Esperado
Precio Objetivo
By TipRanks
20.19% repunte
Estimación a 12 meses
Media 555.87 USD 20.19%
Máximo 641 USD
Mínimo 441 USD
De acuerdo con 25 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Vertex Pharmaceuticals Inc Dist en los últimos 3 meses.
Sentimiento
By Acuity
97 / 351 Clasificación en Salud
Noticias sobre sentimiento de mercado
Coyuntura alcista
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por encima de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Live chat